"Neoplasm Invasiveness" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Ability of neoplasms to infiltrate and actively destroy surrounding tissue.
| Descriptor ID |
D009361
|
| MeSH Number(s) |
C04.697.645 C23.550.727.645
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Neoplasm Invasiveness".
Below are MeSH descriptors whose meaning is more specific than "Neoplasm Invasiveness".
This graph shows the total number of publications written about "Neoplasm Invasiveness" by people in this website by year, and whether "Neoplasm Invasiveness" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 25 | 25 |
| 1995 | 1 | 25 | 26 |
| 1996 | 5 | 33 | 38 |
| 1997 | 3 | 22 | 25 |
| 1998 | 2 | 25 | 27 |
| 1999 | 4 | 34 | 38 |
| 2000 | 1 | 38 | 39 |
| 2001 | 5 | 45 | 50 |
| 2002 | 4 | 33 | 37 |
| 2003 | 11 | 51 | 62 |
| 2004 | 14 | 51 | 65 |
| 2005 | 12 | 67 | 79 |
| 2006 | 6 | 65 | 71 |
| 2007 | 10 | 90 | 100 |
| 2008 | 14 | 70 | 84 |
| 2009 | 8 | 80 | 88 |
| 2010 | 8 | 80 | 88 |
| 2011 | 11 | 89 | 100 |
| 2012 | 7 | 99 | 106 |
| 2013 | 8 | 91 | 99 |
| 2014 | 4 | 91 | 95 |
| 2015 | 4 | 80 | 84 |
| 2016 | 5 | 95 | 100 |
| 2017 | 6 | 86 | 92 |
| 2018 | 5 | 58 | 63 |
| 2019 | 1 | 69 | 70 |
| 2020 | 5 | 46 | 51 |
| 2021 | 1 | 47 | 48 |
| 2022 | 0 | 15 | 15 |
| 2023 | 1 | 22 | 23 |
| 2024 | 3 | 14 | 17 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neoplasm Invasiveness" by people in Profiles.
-
DNA Damage Response Alterations Predict for Neoadjuvant Chemotherapy Sensitivity in Muscle-Invasive Bladder Cancer: A Correlative Analysis of the SWOG S1314 Trial. JCO Precis Oncol. 2024 Nov; 8:e2400287.
-
Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder Cancer. N Engl J Med. 2024 Oct 03; 391(13):1206-1216.
-
A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer. Cancer Res Commun. 2024 Sep 01; 4(9):2444-2453.
-
Rosiglitazone and trametinib exhibit potent anti-tumor activity in a mouse model of muscle invasive bladder cancer. Nat Commun. 2024 Aug 02; 15(1):6538.
-
Correlative Analysis of ATM, RB1, ERCC2, and FANCC Mutations and Pathologic Complete Response After Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Results from the SWOG S1314 Trial. Eur Urol. 2024 Oct; 86(4):297-300.
-
Reply: Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Gu?rin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial. J Urol. 2024 Oct; 212(4):625.
-
CD57 defines a novel cancer stem cell that drive invasion of diffuse pediatric-type high grade gliomas. Br J Cancer. 2024 Jul; 131(2):258-270.
-
ACR Appropriateness Criteria? Pretreatment Evaluation and Follow-Up of Invasive Cancer of the Cervix: 2023 Update. J Am Coll Radiol. 2024 Jun; 21(6S):S249-S267.
-
Epigenetic activation of SOX11 is associated with recurrence and progression of ductal carcinoma in situ to invasive breast cancer. Br J Cancer. 2024 Jul; 131(1):171-183.
-
Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2024 Jun; 25(6):720-730.